
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc. presents an attractive valuation characterized by a notable increase in its price target to $9.25, indicating substantial upside potential. The company’s lead candidate, stenoparib, has demonstrated significant clinical benefits for patients suffering from advanced recurrent ovarian cancer, addressing a critical unmet medical need. Furthermore, the strategic use of proprietary Drug Response Predictor technology enhances patient selection and clinical outcomes, potentially positioning the company favorably within the oncology market.
Bears say
Allarity Therapeutics Inc reported a net loss of $2.37 million, resulting in an earnings per share (EPS) of $(0.15), which was an improvement compared to earlier estimates of $(0.21) but still indicates ongoing financial challenges. The company faces several significant risks, including balance sheet and liquidity issues, potential failure of its product candidates to prove safety and efficacy in clinical trials, and obstacles related to regulatory approvals and commercialization. Additionally, external factors such as competition, changes in healthcare priorities, and investor sentiment toward the biotech sector contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares